Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer

被引:91
作者
Okamura, Kyoko
Harada, Taishi [1 ]
Wang, Shuo
Ijichi, Kayo [2 ]
Furuyama, Kazuto
Koga, Takaomi [2 ]
Okamoto, Tatsuro [3 ]
Takayama, Koichi
Yano, Tokujiro
Nakanishi, Yoichi
机构
[1] Kyushu Univ, Chest Dis Res Inst, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Dept Pathol, Grad Sch Med Sci, Div Pathophysiol & Expt Pathol, Fukuoka 8128582, Japan
[3] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan
关键词
TrkB; BDNF; Survival; Prognosis; Invasion; Lung cancer; GASTROINTESTINAL STROMAL TUMORS; NEUROTROPHIC RECEPTOR TRKB; TYROSINE KINASE; IMATINIB MESYLATE; CARCINOMA; OVEREXPRESSION; ACTIVATION; MUTATIONS; SURVIVAL; TRIAL;
D O I
10.1016/j.lungcan.2012.07.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High expression levels of TrkB and BDNF are associated with aggressive malignant behavior in tumor cells and a poor prognosis in patients with various types of cancer. In this study, we aimed to identify the relationship between TrkB and BDNF expression and clinicopathological variables and prognosis in non-small cell lung cancer (NSCLC). We evaluated TrkB and BDNF expression in the tumor cells of 102 NSCLC patients by immunohistochemistry. Out of all clinicopathological factors examined, only vascular invasion was significantly correlated with TrkB (P=0.010) and BDNF (P=0.015) expression. TrkB-positive tumors had significantly worse disease-free survival (P=0.0094) and overall survival (P=0.0019) than TrkB-negative tumors, and TrkB expression was an independent prognostic factor for disease-free survival (HR 3.735, 95%C.I. 1.560-11.068, P=0.002) and overall survival (HR 4.335, 95%C.I. 1.534-15.963, P=0.004) in multivariate analysis. Finally, our analysis revealed that co-expression of TrkB and BDNF conferred poorer prognosis compared with overexpression of either protein alone. Our results indicate that expression of TrkB and BDNF is associated with poor prognosis in NSCLC patients. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 39 条
  • [1] Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330
  • [2] Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome
    Au, Christy W. H.
    Siu, Michelle K. Y.
    Liao, Xiaoyun
    Wong, Esther S. Y.
    Ngan, Hextan Y. S.
    Tam, Kar Fai
    Chan, Dominic C. W.
    Chan, Queeny K. Y.
    Cheung, Annie N. Y.
    [J]. CANCER LETTERS, 2009, 281 (02) : 151 - 161
  • [3] Bang Yung-Jue, 2011, Ther Adv Med Oncol, V3, P279, DOI 10.1177/1758834011419002
  • [4] THE TRK FAMILY OF NEUROTROPHIN RECEPTORS
    BARBACID, M
    [J]. JOURNAL OF NEUROBIOLOGY, 1994, 25 (11): : 1386 - 1403
  • [5] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [6] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Szczesna, Aleksandra
    Juhasz, Erzsebet
    Esteban, Emilio
    Molinier, Olivier
    Brugger, Wolfram
    Melezinek, Ivan
    Klingelschmitt, Gaelle
    Klughammer, Barbara
    Giaccone, Giuseppe
    [J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
  • [7] Neurotrophins and their receptors: A convergence point for many signalling pathways
    Chao, MV
    [J]. NATURE REVIEWS NEUROSCIENCE, 2003, 4 (04) : 299 - 309
  • [8] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [9] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    DeMatteo, Ronald P.
    Ballman, Karla V.
    Antonescu, Cristina R.
    Maki, Robert G.
    Pisters, Peter W. T.
    Demetri, George D.
    Blackstein, Martin E.
    Blanke, Charles D.
    von Mehren, Margaret
    Brennan, Murray F.
    Patel, Shreyaskumar
    McCarter, Martin D.
    Polikoff, Jonathan A.
    Tan, Benjamin R.
    Owzar, Kouros
    [J]. LANCET, 2009, 373 (9669) : 1097 - 1104
  • [10] Somatic mutations affect key pathways in lung adenocarcinoma
    Ding, Li
    Getz, Gad
    Wheeler, David A.
    Mardis, Elaine R.
    McLellan, Michael D.
    Cibulskis, Kristian
    Sougnez, Carrie
    Greulich, Heidi
    Muzny, Donna M.
    Morgan, Margaret B.
    Fulton, Lucinda
    Fulton, Robert S.
    Zhang, Qunyuan
    Wendl, Michael C.
    Lawrence, Michael S.
    Larson, David E.
    Chen, Ken
    Dooling, David J.
    Sabo, Aniko
    Hawes, Alicia C.
    Shen, Hua
    Jhangiani, Shalini N.
    Lewis, Lora R.
    Hall, Otis
    Zhu, Yiming
    Mathew, Tittu
    Ren, Yanru
    Yao, Jiqiang
    Scherer, Steven E.
    Clerc, Kerstin
    Metcalf, Ginger A.
    Ng, Brian
    Milosavljevic, Aleksandar
    Gonzalez-Garay, Manuel L.
    Osborne, John R.
    Meyer, Rick
    Shi, Xiaoqi
    Tang, Yuzhu
    Koboldt, Daniel C.
    Lin, Ling
    Abbott, Rachel
    Miner, Tracie L.
    Pohl, Craig
    Fewell, Ginger
    Haipek, Carrie
    Schmidt, Heather
    Dunford-Shore, Brian H.
    Kraja, Aldi
    Crosby, Seth D.
    Sawyer, Christopher S.
    [J]. NATURE, 2008, 455 (7216) : 1069 - 1075